Efficacy of Trimebutine Maleate (Trimedat®) in the Treatment of Patients with Functional Dyspepsia: Results of the “TREND” Observational Study

Aim. This research is aimed at investigating the experience of applying trimebutine maleate in the daily practice of physicians managing patients with functional dyspepsia syndrome (FDS).

Materials and methods. The study included 100 patients diagnosed with FDS. The patients were asked to complete a 7 × 7 and SF36 questionnaires before and on the 7th, 14th, 28th days of treatment. The treatment was performed using trimebutine (Trimedat®) in a standard dosage of 200 mg × 3 times a day for 28 days.

Results. In the group under study, 45 (45 %), 3 (3 %) and 52 (52 %) patients suffered from epigastric pain syndrome (EPS), postprandial distress syndrome (PPDS) and a combination of both syndromes, respectively. The combination of FDS with gastroesophageal reflux disease (GERD) was noted in 15 patients (15 %). Irritable bowel syndrome (IBS) was present in 21 cases (21 %). Trimebutine maleate (Trimedat®) has been proven effective in all FDS forms, such as EPS, PPDS and their combination. In the course of treatment, the average score of the patients’ physical and mental health increased from 48.02 ± 5.62 to 52.97 ± 4.17 points (p < 0.0001), and from 48.48 ± 10.83 up to 51.79 ± 8.51 points (p < 0.0001), respectively.

Conclusion. The main clinical forms of functional dyspepsia syndrome (EPS and PPDS) are frequently manifested in combination either with each other (52 %), or with IBS (21 %) and GERD (15 %). The use of trimebutine in the treatment of patients with FDS is shown to result in a decrease in the severity of its main symptoms and a reliable increase in the quality of patients’ life. 

1. Drossman D.A., Hasler W.L. Rome IV — Functional GI Disorders: Disorders of Gut — Brain Interaction. Gastroenterology. 2016;150:1257–61.

2. Ivashkin V.T., Mayev I.V., Sheptulin A.A., Lapina T.L., Trukhmanov A.S., Kartavenko I.M., Kiprianis V.A., Okhlobystina O.Z. Diagnosis and treatment of the functional dyspepsia: clinical guidelines of the Russian Gastroenterological Association. Ross z gastroentrerol gepatol koloproktol. 2017;27(1):50–61 (In Rus.). DOI: 10.22416/1382-4376-2017-27-1-50-61.

3. Ivashkin V.T., Sheptulin A.A., Kiprianis V.A. Functional dyspepsia. Moscow: Medpress-inform, 2017. 142 p. (In Rus.).

4. Delvaux M., Wingate D. Trimebutine: mechanism of action, effects on gastrointestinal function and clinical results. J Int Med Res. 1997;25(5):225–46.

5. Aktas A., Caner B., Ozturk F., Bayhan H., Narin Y., Mentes T. The effect of trimebutine maleate on gastric emptying in patients with non-ulcer dyspepsia. Ann Nucl Med. 1999;13(4):231–4.

6. Nizhevich A.A., Valeeva D.S., Sataev V.U., Gafurova K.A., Akhmadeeva E.N., Akhmetshin R.Z. Current approaches to treatment of functional dyspepsia in childhood. Pediatric Nutrition. 2017;3(15):5–11 (In Rus.).

7. Terentyeva N.G., Terentyeva E.V. Evaluation of the effectiveness of drug correction of the physiological gastric function using information technologies. Theory and Practice of Modern Science. 2017;1(19):1096–101 (In Rus.).

8. Kamiya T., Nagao T., Andou T., Misu N., Kobayashi Y., Hirako M., Hara M., Fujinami T. Effects of trimebutine maleate on gastric motility in patients with gastric ulcer. J Gastroenterol. 1998;33(6):823–7.

9. Kountouras J., Chatzopoulos D., Zavos C., et al. Efficacy of trimebutine therapy in patients with gastroesophageal reflux disease and irritable bowel syndrome. Hepatogastroenterology. 2002;49(43):193–7.

10. Ivashkin V.T., Sheptulin A.A., Poluektova Ye.A., Reykhart D.V., Belostotsky A.V., Drozdova A.A., Arnautov V.S. Potential of 7 × 7 (7 symptoms per 7 days) questionnaire in assessment of symptom dynamics of functional dyspepsia and irritable bowel syndrome. Rus J Gastroenterol Hepatol Coloproctol. 2016;26(3):24–32 (In Rus.).

11. Ivashkin V.T., Poluektova Ye.A., Reykhart D.V., Shifrin O.S., Beniashvili A.G., Lyashenko O.S., Belostotsky A.V. Efficacy of drugs most commonly prescribed at functional gastrointestinal diseases (functional dyspepsia syndrome and irritable bowel syndrome) observational study results. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2016;26(4):14–23 (In Rus.).

12. Okhlobystina O.Z. Some features of pathogenesis, clinical picture, diagnosis and treatment of functional dyspepsia syndrome: Published summary of PhD thesis of the Candidate of Medical Sciences. Moscow, 2007 (In Rus.).

13. Manabe N., Haruma K., Hata J., Imamura H., Kamada T., Kusunoki H., et al. Clinical characteristics of Japanese dyspeptic patients: is the Rome III classification applicable?. Scand J Gastroenterol. 2010;45:567–72.

14. Aziz I., Palsson O.S., Törnblom H., Sperber A.D., Whitehead W.E., Simrén M. Epidemiology, clinical characteristics, and associations for symptom-based Rome IV functional dyspepsia in adults in the USA, Canada, and the UK: a cross-sectional population-based study. Lancet Gastroenterol Hepatol. 2018;3(4):252–62.

15. Kim S.E., Kim N., Lee J., Park K.S., Shin J.E., Nam K., et al. Prevalence and Risk Factors of Functional Dyspepsia in Health Check-up Population: A Nationwide Multicenter Prospective Study. J Neurogastroenterol Motil. 2018. DOI: 10.5056/jnm18068

16. Kaji M.1., Fujiwara Y., Shiba M., Kohata Y., Yamagami H., Tanigawa T., et al. Prevalence of overlaps between GERD, FD and IBS and impact on health-related quality of life. J Gastroenterol Hepatol. 2010;25(6):1151–6.

17. Rasmussen S., Jensen T.H., Henriksen S.L., et al. Overlap of symptoms of gastroesophageal reflux disease, dyspepsia and irritable bowel syndrome in the general population. Scand J Gastroenterol. 2015;50(2):162–9.

18. Young Joo Yang, Chang Seok Bang, et al. Prokinetics for the treatment of functional despepsia: Bayesian network meta-analysis. BMC Gastroenterology 2017.

19. Sobczak M., Salaga M., Storr M.A., Fichna J. Physiology, signaling, and pharmacology of opioid receptors and their ligands in the gastrointestinal tract: current concepts and future perspectives. J Gastroenterol. 2014;49(1):24–45.

20. Taniyama K., Sano I., Nakayama S., Matsuyama S., Takeda K., Yoshihara C., Tanaka C. Dual effect of trimebutine on contractility of the guinea pig ileum via the opioid receptors. Gastroenterology. 1991;101(6):1579–87.

21. Nagasaki M., Komori S., Ohashi H. Effect of trimebutine on voltage-activated calcium current in rabbit ileal smooth muscle cells. Br J Pharmacol. 1993 Sep;110(1):399–403.

22. Takenaga H., Magaribuchi T., Tamaki H. Effects of trimebutine maleate (TM-906) on the spontaneous contraction of isolated duodenum and ileum in both guinea pigs and rabbits. Jpn J Pharmacol. 1986;40(1):13–20.

23. Okano H., Saeki S., Inui A., Kawai Y., Ohno S., Morimoto S., Ohmoto A., Nakashima T., Miyamoto M., Okita M., et al. Effect of trimebutine maleate on emptying of stomach and gallbladder and release of gut peptide following a solid meal in man. Dig Dis Sci. 1993;38(5):817–23.